Brazilian Butt Lift in India and UAE | Complete Patient Guide

• BMI between 22 and 32 is optimal; patients must have sufficient donor fat in the abdomen, flanks, or thighs (a minimum of approximately 1,000 mL harvestable fat is generally required for meaningful augmentation)

• Non-smokers, or patients who have abstained from nicotine products (including e-cigarettes and patches) for at least 6 weeks prior to surgery, as nicotine impairs microvascular perfusion and fat graft survival

• Patients in good general health with ASA Physical Status Classification I or II; fitness assessment includes: complete blood count (CBC), coagulation profile (PT/INR, aPTT), comprehensive metabolic panel, HbA1c (diabetes screening), ECG, and chest X-ray

• Women and men aged 18–55 seeking gluteal volume enhancement, correction of gluteal ptosis, or improvement of waist-to-hip ratio who are psychologically stable with realistic aesthetic expectations

• Patients with a stable body weight for at least 6 months; significant post-operative weight fluctuation directly impacts fat graft retention and long-term aesthetic outcome

• Patients requiring formal DVT risk stratification using the Caprini Risk Assessment Model prior to procedure planning, particularly international travellers

Contraindications:

• BMI above 35 (significantly elevated anaesthetic and surgical risk; fat embolism risk increases)

• Active coagulopathy, anticoagulant therapy that cannot be safely bridged, or history of thrombophilia without haematological clearance

• Uncontrolled diabetes mellitus (HbA1c > 8.0%), active infection, or immunosuppression

• Severe cardiac or pulmonary comorbidity (ASA III or above without cardiac/pulmonary specialist clearance)

• Active or recent malignancy

• Unrealistic expectations or body dysmorphic disorder (BDD) identified during mandatory psychological screening

• Insufficient donor fat volume to achieve the patient's desired outcome safely

Standard Technique — Tumescent Liposuction with Coleman Fat Grafting:

The foundational BBL protocol involves infiltration of tumescent solution (saline with dilute epinephrine and lidocaine) into donor sites, followed by liposuction using 3–4 mm cannulas. Harvested fat is processed via closed-system centrifugation (Coleman protocol) and reinjected in multiple micro-passes using 4 mm blunt-tipped cannulas strictly in the subcutaneous gluteal plane. This technique delivers reliable results with predictable graft retention and remains the most widely performed approach globally.

High-Definition BBL (HD-BBL):

An advanced evolution utilising VASER (Vibration Amplification of Sound Energy at Resonance) ultrasound-assisted liposuction for donor site harvest. VASER selectively emulsifies adipose tissue while preserving the fibrovascular stromal architecture and ADSCs, yielding a fat graft with superior cellular viability compared to standard suction-assisted liposuction. HD-BBL enables simultaneous high-definition sculpting of the abdomen (4D Hi-Def liposculpture) and precise three-dimensional gluteal augmentation. This is the preferred approach for athletic patients seeking defined muscular aesthetics alongside volume.

Power-Assisted Liposuction (PAL) BBL:

Utilises reciprocating mechanical cannula motion (MicroAire system) to reduce surgeon fatigue and improve fat harvest uniformity in high-volume cases. PAL produces minimal thermal injury to adipocytes and is particularly suited for fibrous donor areas (back rolls, upper arms, medial thighs). Fat processing post-harvest follows the same centrifugation or filtration protocols as the standard technique.

Ultrasound-Guided Injection Protocol:

A critical safety advancement now adopted by leading accredited centres. Real-time intraoperative ultrasonography is used during fat injection to confirm cannula tip position within the subcutaneous layer at all times, providing visualised proof of compliance with the ISAPS/ASPS intramuscular injection prohibition. This technology is available at GAF Healthcare partner hospitals in India (Mumbai, Delhi, Bengaluru) and in Dubai.

Fat Processing Technologies:

• Revolve™ System (LifeScience Solutions): A closed, single-use washing and filtration platform that removes tumescent fluid, blood, and free lipids in under 3 minutes, producing high-viability adipocyte concentrate without centrifugation-related mechanical stress.

• PureGraft™ System: Membrane-based filtration offering gentler processing, preferred in centres prioritising ADSC preservation for volume-sensitive cases.

• Centrifuge Protocol (Coleman/Rohrich): 3,000 rpm × 3 minutes; gold-standard reference technique against which other methods are benchmarked in peer-reviewed literature.

Complementary Adjuncts:

• Platelet-Rich Plasma (PRP) admixture with fat graft: Some surgeons incorporate autologous PRP to enhance angiogenesis and graft take, though current evidence is emerging rather than definitive.

• Renuvion (J-Plasma) Subdermal Skin Tightening: Radiofrequency/helium plasma device used adjunctively at donor sites to improve skin retraction, particularly in patients with mild skin laxity post-liposuction.

Phase 1 — Pre-Operative Preparation (4–6 weeks before surgery): GAF Healthcare coordinates a telemedicine consultation with the treating plastic surgeon. High-resolution full-body photographs are submitted for digital morphing and surgical planning. Laboratory investigations (CBC, coagulation profile, metabolic panel, HbA1c, ECG) are completed in the patient's home country and reviewed remotely. Caprini DVT risk score is calculated. Patients are instructed to discontinue NSAIDs, aspirin, vitamin E, herbal supplements, and hormonal contraceptives 2 weeks prior. Nicotine cessation is confirmed at 6 weeks. Compression garments and post-operative supplies are pre-ordered. Medical visa (India) or entry visa (UAE) is arranged by GAF Healthcare's patient coordinator.

Phase 2 — Arrival and Final Assessment (1–2 days before surgery): Patient arrives at the destination city. GAF Healthcare airport transfer service delivers the patient to partner hotel or hospital accommodation. In-person surgical consultation confirms operative plan, consent is obtained, anaesthetic assessment is completed by the anaesthesiologist, and final pre-operative blood work is reviewed. Surgical site marking is performed with the patient standing to account for gravitational fat distribution.

Phase 3 — The Operative Day: General anaesthesia or deep sedation with tumescent technique is administered. The procedure typically lasts 3–5 hours depending on volume and technique. Liposuction of donor areas is completed first (abdomen, flanks, lumbar, thighs) harvesting 2,000–4,000 mL of fat emulsion; after processing, a net volume of 600–1,500 mL of purified fat per gluteal cheek is available for injection depending on retention targets. Fat is injected in layered retrograde passes exclusively in the subcutaneous gluteal plane under ultrasound guidance where available. Incisions (3–4 mm) are closed with absorbable sutures. Compression garment is applied immediately in theatre.

Phase 4 — Immediate Post-Operative Period (Days 1–7): Patient is monitored overnight (1–2 days hospital stay). Pain is managed with multimodal analgesia (scheduled paracetamol, NSAIDs re-introduced after 48 hours, low-dose opioid rescue). Prophylactic low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg subcutaneously daily) is administered for DVT prophylaxis for minimum 7–10 days. Sitting directly on the buttocks is prohibited for the first 8 weeks; patients use a BBL pillow or prone/side-lying positions. Drain output is monitored; drains are removed at 24–48 hours. The compression garment is worn continuously for 6 weeks.

Phase 5 — Early Recovery (Weeks 2–4): Surgical review at Day 7 and Week 3. Swelling and bruising at donor sites typically resolve 60–70% by Week 4. Post-operative lymphatic drainage massage is initiated at Day 10 to reduce oedema and improve contour. Light walking is encouraged from Day 3; return to desk work (remote/office) is possible at Week 2–3. The patient remains in-country during this phase under GAF Healthcare follow-up coordination.

Fit-to-Fly Clearance (Week 3–4): Formal DVT risk reassessment is performed at Week 3. Long-haul flight clearance requires: absence of active swelling or wound complications, stable vital signs, Caprini score reassessment, and surgeon sign-off. Patients flying home wear graduated compression stockings, take 1 aspirin daily for 2 weeks post-clearance, perform in-seat calf exercises every 30 minutes, and are advised to stand and walk the aisle hourly on flights exceeding 4 hours.

Phase 6 — Long-Term Recovery (Months 1–6): Final gluteal volume stabilises at 6–12 months as non-integrated fat is resorbed (approximately 30–40% volume loss is expected in the first 6 months, which surgeons account for by over-injecting strategically). Full exercise resumption (including weight training and cycling) is permitted at 8–10 weeks. Final aesthetic result is assessed at 6-month and 12-month virtual follow-up appointments coordinated by GAF Healthcare.